ProHealth fibromyalgia Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Namenda (memantine): A Potential NEW Treatment for Fibromyalgia

Daytime Napping Linked to Increased Fibromyalgia Symptom Severity

Minimizing Fibromyalgia Symptoms: Valuable Lessons from Childhood

An Update on Drugs Used for Treating Fibromyalgia

Respiratory Sinus Arrhythmia and Its Association with Pain in Women with Fibromyalgia

SURVEY: What Triggered Your Illness?

An Evaluation of Selective Serotonin Reuptake Inhibitors for Fibromyalgia

Why I Became a Fibromyalgia Advocate

Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?

5 Tips for When Motivation Runs Out

 
Print Page
Email Article

Results of Switching Fibromyalgia Patients from Cymbalta to Savella

  [ 5 votes ]   [ Discuss This Article ]
www.ProHealth.com • May 14, 2013


Editor's comment:  There are currently three drugs that have received FDA approval for the treatment of fibromyalgia (brand names: Lyrica, Cymbalta and Savella).  Each one has roughly a 30% success rate for improving FM symptoms.  Therefore, when one medication is not helping a patient, it is not unusual for the treating physician to switch the patient to one of the other approved drugs.  The purpose of this study was to assess the results of switching fibromyalgia patients who were not being helped by duloxotine (Cymbalta) to milnacipran (Savella).  The researchers sought to answer two primary questions: (1) Would patients experience any improvements in pain or other symptoms after switching medications? (2) Can patients be switched from one medication to the other without first tapering down the dosage of the first medication?

Note: You may read the full text of this article free HERE.


Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study

By Lucinda Bateman, et al.

Abstract:

BACKGROUND: The purpose of this study was to evaluate the safety, tolerability, and efficacy of milnacipran following a direct switch from duloxetine in fibromyalgia patients experiencing inadequate clinical response to duloxetine after receiving treatment for 6 weeks or longer.

METHODS: This exploratory study included 107 patients with fibromyalgia who had been treated with duloxetine 60 mg/day for at least 4 weeks prior to enrollment. Following a 2-week open-label period on duloxetine, patients who had visual analog scale pain scores ? 40 and were dissatisfied with current treatment were randomized 4:1 to milnacipran 100 mg/day (n = 86) or placebo (n = 21) for 10 weeks of double-blind treatment. The small placebo group was included solely to blind the study and minimize expectation bias among patients and investigators, and there was no preplanned statistical comparison between treatment groups.

The primary efficacy parameter was the percentage of patients rating themselves as "much improved" or "very much improved" on the Patient Global Impression of Change (PGIC) at the final visit. Other efficacy parameters included changes in one-week recall visual analog scale pain, Fibromyalgia Impact Questionnaire Revised (FIQR), and Multiple Ability Self-Report Questionnaire (MASQ).

RESULTS: Of patients switched to milnacipran, 32.9% were classified as PGIC responders, and they also demonstrated improvement in visual analog scale pain, FIQR total, and MASQ total scores (mean changes from baseline were -12.3, -7.77, and -2.39, respectively).

Nausea and dizziness were the most common treatment-emergent adverse events in patients switched to milnacipran, reported in 21% and 15%, respectively, of patients in this group.

CONCLUSION: Results from this exploratory study suggest that switching from duloxetine to milnacipran may be beneficial in some patients with fibromyalgia who have an inadequate response to duloxetine. Further research investigating the efficacy and safety of switching fibromyalgia therapies is warranted.

Source: Journal of Pain Research, April 26, 2013. By Lucinda Bateman, Robert H Palmer, Joel M Trugman, and Yuhua Lin. Fatigue Consultation Clinic, Salt Lake City, UT.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Guaifenesin FA™ Guaifenesin FA™
Natural Expectorant Relieves Chest Congestion
Fibro Freedom™ Fibro Freedom™
Soothes, strengthens & revitalizes
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth

Natural Remedies

Complete and Natural Menopause Relief Complete and Natural Menopause Relief
The Surprising Benefits of Probiotics - What You Didn't Know The Surprising Benefits of Probiotics - What You Didn't Know
Cocoa's Polyphenol Riches – All the Health Benefits without the Sugar, Calories and Guilt Cocoa's Polyphenol Riches – All the Health Benefits without the Sugar, Calories and Guilt
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Fatigue & Fibro Fog: Could You Have a B-12 Deficiency? Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing